我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
192
21 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1976
进行中（未招募）
7
3.6%
已完成
108
56.3%
Enrolling By Invitation
1
0.5%
尚未招募
13
6.8%
招募中
45
23.4%
Unknown
17
8.8%
撤回
暂无批准数据
- A clinical trial reveals that fenofibrate, when added to mesalamine, significantly improves clinical outcomes in patients with mild to moderate ulcerative colitis. - The study demonstrates that fenofibrate reduces inflammatory markers such as NLRP3 and fecal calprotectin, while increasing SIRT1 and AMPK levels. - Patients receiving fenofibrate in combination with mesalamine showed higher response and remission rates compared to those treated with mesalamine alone. - The findings suggest fenofibrate as a safe and tolerable adjunct therapy, warranting further investigation for ulcerative colitis treatment.
